EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
What Changes at Scale, and How Do You Know?
A pharmaceutical process that performs reliably on a few grams of material can behave very differently at pilot or commercial scale The temperature setpoint that worked on the bench the mixing time that delivered a uniform blend the feed rate that kept a reaction on track none of these is guaranteed to mean the same thing in larger equipment When that difference goes...
Advisory Board
KNOWLEDGE BANK
-
Articles
How Technology Is Changing Revenue Management In The Pharmaceutical Industry
Pharmaceutical companies have never had straightforward revenue models Theres tiered national pricing parallel trade between EU member states rebate agreements with payers royalty arrangements for licensed compounds and huge numbers of SKUs moving through wholesalers and specialist pharmacies
Europe’s CGT Manufacturing Readiness: Challenges and Opportunities
Few areas of pharmaceutical innovation carry as much promise or as much operational fragility as cell and gene therapy A single dose can replace years of chronic treatment yet each batch may begin with a patients own blood travel across borders under cryogenic conditions and depend on viral
Navigating Gene Therapy Regulations: Compliance Strategies for Successful Implementation
Gene therapy holds immense promise for treating a wide range of genetic disorders and diseases However its implementation requires strict adherence to regulatory guidelines to ensure safety efficacy and ethical considerations
Rethinking Make-or-Buy: Strategic Manufacturing Decisions in Pharma
Few strategic decisions in pharmaceutical operations carry as much longterm consequence as the choice of what to make and what to buy and few are revisited as rarely Network footprints agreed a decade ago partners selected during a capacity crunch technology transfers completed under launch pressure these choices harden into architecture They stop looking like decisions and start looking like the...
How GLP-1 Medicines Are Changing Pharmaceutical Manufacturing Priorities
Pharmaceutical manufacturing networks are usually designed around forecasts that move in single digits GLP receptor agonists broke that assumption Within a few years a therapeutic class once associated mainly with type diabetes became a massmarket treatment for chronic weight management cardiovascular risk reduction and a widening list of related conditions Demand did not grow in a straight line...
Medical Devices and Pharma: A Symbiotic Relationship for Improved Healthcare
The healthcare industry is continually evolving driven by technological advancements and innovative approaches to patient care Among the most significant developments is the symbiotic relationship between medical devices
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
Europe’s CGT Manufacturing Readiness: Challenges and Opportunities
Lakshmi
Europe has the science to lead in cell and gene therapy (CGT), yet manufacturing capacity, not discovery, increasingly decides which therapies reach patients. This article examines Europe’s CGT...
-
2
Navigating Gene Therapy Regulations: Compliance Strategies for Successful Implementation
Kate Williamson
Navigating gene therapy regulations requires a comprehensive approach integrating scientific expertise, regulatory compliance, and ethical considerations. This article explores key compliance strategi...
-
3
Rethinking Make-or-Buy: Strategic Manufacturing Decisions in Pharma
Lakshmi
For three decades, pharmaceutical manufacturers treated outsourcing as the default answer to capacity, cost and speed pressures. Supply disruptions, modality complexity and regulatory scrutiny have si...
-
4
How GLP-1 Medicines Are Changing Pharmaceutical Manufacturing Priorities
Lakshmi
GLP-1 medicines have moved from a diabetes niche to one of the largest demand shocks the pharmaceutical industry has ever absorbed. Supply shortages that ran from 2022 into 2025, the arrival of oral f...
-
5
Medical Devices and Pharma: A Symbiotic Relationship for Improved Healthcare
Kate Williamson
The symbiotic relationship between medical devices and pharmaceuticals revolutionizes healthcare by enhancing diagnostics, treatment, and disease management. This integration fosters personalized medi...
press releases Read more...
Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development
Cancer Research UK and Dewpoint Therapeutics today announced a collaboration and licence agreement to advance DPTX a potential firstinclass small molecule modulator of MYC condensates into clinical development
Instem and Histofy Launch Provantis® Compose, Accelerating Nonclinical Study Reporting Through AI-Assisted Automation and Expert Oversight
Instem a leading provider of software for life sciences research and regulatory operations across preclinical and clinical RD today announced a strategic partnership with Histofy to launch Provantis Compose a powerful new module designed to automate and accelerate the creation of final study reports...
Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion
Rosemont Pharmaceuticals Holdings Inc Rosemont a global specialty pharmaceutical company focused on designing and delivering medicines around patients needs today announced that it has entered into a definitive merger agreement
Asimov and Emergent Biosolutions Announce Cell Line Development Partnership to Advance Novel Antibodies Against Ebola
Asimov the company building an AInative synthetic biology platform to advance therapeutic development and Emergent Biosolutions NYSE EBS a leading global public health company today announced a cell line development partnership
Events Read more...
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
25 - 25
Nov 2026What’s Next for Pharma Marketing in 2027
Landesmuseum Zürich, Zurich, S...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
02 - 04
Dec 2026Genome Informatics 2026
Wellcome Genome Campus, UK
03 - 04
Dec 2026Pharmacy and Pharmaceutical Conference
Madrid, Spain
LATEST NEWS Read more...
Erasca Partners with Bristol Myers Squibb to Study ERAS-0015 Combination Therapy for Pancreatic Cancer
Erasca Inc a clinicalstage precision oncology company focused on developing treatments for cancers driven by the RASMAPK signalling pathway has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb BMS
Libtayo Receives EU Approval for Extended Dosing and Shorter Infusion Times Across Six Cancer Indications
Regeneron Pharmaceuticals has received European Commission EC approval for an alternative dosing schedule for Libtayo cemiplimab across all six of its approved indications for skin lung and cervical cancers in the European Union EU
FDA approves Roche’s Wilserdly for ER-positive, ESR1-mutated advanced breast cancer
Roche has received approval from the US Food and Drug Administration FDA for Wilserdly giredestrant in combination with everolimus to treat adults with oestrogen receptor ERpositive human epidermal growth factor receptor HERnegative ESRmutated locally advanced or metastatic breast cancer
European Commission approves Revolution Medicines’ RASONQUE for metastatic pancreatic cancer
Revolution Medicines has received European Commission EC approval for RASONQUE daraxonrasib to treat adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic therapy The medicine is taken once daily as an oral tablet and is approved for patients with or witho...
Immuneering and Astellas to Evaluate Combination Treatments for CLDN18.2-Expressing Pancreatic Cancer
Immuneering Corporation Nasdaq IMRX has entered into a clinical trial collaboration and supply agreement with Astellas Pharma Global Development Inc a subsidiary of Astellas Pharma Inc TSE to evaluate combination treatments for patients with pancreatic cancer whose tumours express CLDN
Takeda Launches ORZEYFUL (Oveporexton), the First Orexin Agonist for Narcolepsy Type 1, in the US
Takeda TSE NYSE TAK has announced the US launch of ORZEYFUL oveporexton CIV now available by prescription for adults with narcolepsy type NT also known as narcolepsy with cataplexy The medicine is the first and only orexin agonist available for this condition









